Daniel Legault, CEO and Director of Antibe Therapeutics: More Licensing Deals to Come

TL;DR

A biotech company has developed a game-changing pain therapeutic drug with a significantly lower risk of gastrointestinal side effects.

Transcript

during bestie conference in Toronto and I'm speaking with done without the anti a pair of peanuts thank you for being here today Jen it's a pleasure to do so today we didn't talk a little bit about as you therapeutics now the company has had some really exciting news lately I didn't want to share a little bit more with investors of what this means ... Read More

Key Insights

• 👤 Gastrointestinal side effects are a significant problem associated with anti-inflammatory painkillers, affecting around 20% of users.
• 👾 The company's drug showed promising results in a phase 2b study, indicating its potential to be a game-changer in pain therapeutics.
• 👨‍🎨 By developing alternative drugs with reduced side effects, the company aims to provide safer options for pain management, especially as an alternative to opioids.
• 🥺 The success of their drug could lead to regulatory approvals and eventually an over-the-counter availability.
• 🇺🇸 The company is targeting large markets like the United States, Japan, and Europe for strategic partnerships and global distribution.
• 🇦🇬 The opioid crisis has increased the demand for nonsteroidal anti-inflammatory painkillers as alternatives. However, these painkillers often have damaging effects on the gastrointestinal system.
• 👋 The company's drug for general and osteoarthritis pain has shown promising results, showcasing its potential to be the best-in-class treatment.

Questions & Answers

Q: What is the main problem the company is trying to solve with their pain therapeutic drug?

The company aims to address the issue of gastrointestinal side effects associated with anti-inflammatory painkillers, which affects about 20% of people taking these medications.

Q: What were the results of the phase 2b study conducted by the company?

The study showed that the company's drug had a conservation rate of 42% compared to naproxen, a commonly prescribed painkiller. It also had a low side effect rate of 2.5%.

Q: What are the three main drugs the company is developing?

The company is focusing on a drug for general and osteoarthritis pain, a super-strong drug as a substitute for opioids, and a low-dose aspirin with reduced digestive system side effects.

Q: What are the future milestones investors can look forward to?

The company is planning to conduct a larger controlled Phase 2 trial to further validate the pain effectiveness and gastrointestinal safety of their drug. They are also actively pursuing regional licensing deals and strategic market partnerships.

Summary & Key Takeaways

• The company has developed a pain therapeutic drug that aims to solve the problem of gastrointestinal side effects commonly experienced by people taking anti-inflammatory painkillers.

• They have completed a successful phase 2b study in humans, with their drug showing a 42% conservation rate and a 2.5% solution compared to the commonly prescribed drug naproxen.

• The company's lead drug targets general and osteoarthritis pain, and they are also developing a super-strong drug as an alternative to opioids and a low-dose aspirin with reduced digestive system side effects.